Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2016, Article ID 8237264, 14 pages
http://dx.doi.org/10.1155/2016/8237264
Research Article

Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

1Department of Pharmacobiology, Research and Advanced Studies Center, National Polytechnic Institute (IPN), Calzada de los Tenorios No. 235, Colonia Granjas Coapa, Tlalpan, 14330 Mexico City, Mexico
2Department of Pharmacology, National Institute of Cardiology Ignacio Chávez, Juan Badiano No. 1, Colonia Sección XVI, Tlalpan, 14080 Mexico City, Mexico
3Department of Neurochemistry, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Insurgentes Sur No. 3877, Colonia La Fama, Tlalpan, 14269 Mexico City, Mexico

Received 7 January 2016; Accepted 18 February 2016

Academic Editor: Yanbo Fan

Copyright © 2016 Víctor Hugo Oidor-Chan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. A. DeFronzo, “Pharmacologic therapy for type 2 diabetes mellitus,” Annals of Internal Medicine, vol. 131, no. 4, pp. 281–303, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. S. P. Gray and K. Jandeleit-Dahm, “The pathobiology of diabetic vascular complications—cardiovascular and kidney disease,” Journal of Molecular Medicine, vol. 92, no. 5, pp. 441–452, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. P.-Y. Zhang, “Cardiovascular disease in diabetes,” European Review for Medical and Pharmacological Sciences, vol. 18, no. 15, pp. 2205–2214, 2014. View at Google Scholar
  4. M. Aragno, R. Mastrocola, C. Medana et al., “Oxidative stress-dependent impairment of cardiac-specific transcription factors in experimental diabetes,” Endocrinology, vol. 147, no. 12, pp. 5967–5974, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. R. B. Wichi, V. Farah, Y. Chen, M. C. Irigoyen, and M. Morris, “Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 292, no. 3, pp. R1184–R1189, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Li and U. Förstermann, “Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease,” Current Opinion in Pharmacology, vol. 13, no. 2, pp. 161–167, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. A. Bulhak, C. Jung, C.-G. Östenson, J. O. Lundberg, P.-O. Sjöquist, and J. Pernow, “PPAR-α activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 3, pp. H719–H727, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Dumitrescu, R. Biondi, Y. Xia et al., “Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BHIN4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 38, pp. 15081–15086, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. U. Förstermann and W. C. Sessa, “Nitric oxide synthases: regulation and function,” European Heart Journal, vol. 33, no. 7, pp. 829–837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Magenta, S. Greco, M. C. Capogrossi, C. Gaetano, and F. Martelli, “Nitric oxide, oxidative stress, and p66Shc interplay in diabetic endothelial dysfunction,” BioMed Research International, vol. 2014, Article ID 193095, 16 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Eldor, R. A. DeFronzo, and M. Abdul-Ghani, “In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion,” Diabetes Care, vol. 36, supplement 2, pp. S162–S174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Holden and J. D. Tugwood, “Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences,” Journal of Molecular Endocrinology, vol. 22, no. 1, pp. 1–8, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. L. G. Cervantes-Pérez, M. D. Ibarra-Lara, B. Escalante et al., “Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension,” European Journal of Pharmacology, vol. 685, no. 1–3, pp. 108–115, 2012. View at Publisher · View at Google Scholar
  14. T.-L. Yue, W. Bao, B. M. Jucker et al., “Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury,” Circulation, vol. 108, no. 19, pp. 2393–2399, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. N. S. Wayman, Y. Hattori, M. C. McDonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” The FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Barreto-Torres, R. Parodi-Rullán, and S. Javadov, “The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats,” International Journal of Molecular Sciences, vol. 13, no. 12, pp. 7694–7709, 2012. View at Publisher · View at Google Scholar
  17. L. Ibarra-Lara, E. Hong, E. Soria-Castro et al., “Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia,” Journal of Cardiovascular Pharmacology, vol. 60, no. 4, pp. 323–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Flohé and F. Otting, “Superoxide dismutase assays,” Methods in Enzymology, vol. 105, pp. 93–104, 1984. View at Publisher · View at Google Scholar · View at Scopus
  19. F. A. Tenorio and L. P. G. del Valle, “Validación de un método analítico espectrofotométrico para la cuantificación de metabolitos estables de óxido nítrico en fluidos biológicos Validation of a spectrophotometric analytical method for quantifying stable,” Revista Mexicana de Ciencias Farmacéuticas, vol. 36, no. 1, pp. 31–41, 2005. View at Google Scholar
  20. Y. Hu, Y. Chen, L. Ding et al., “Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 38, pp. 15401–15406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Narravula and S. P. Colgan, “Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor α expression during hypoxia,” Journal of Immunology, vol. 166, no. 12, pp. 7543–7548, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Chavali, S. C. Tyagi, and P. K. Mishra, “Predictors and prevention of diabetic cardiomyopathy,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 151–160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. W. Schaffer, B. H. Tan, and G. L. Wilson, “Development of a cardiomyopathy in a model of noninsulin-dependent diabetes,” The American Journal of Physiology, vol. 248, no. 2, pp. H179–H185, 1985. View at Google Scholar · View at Scopus
  24. D. Aronson, A. Musallam, J. Lessick et al., “Impact of diastolic dysfunction on the development of heart failure in diabetic patients after acute myocardial infarction,” Circulation: Heart Failure, vol. 3, no. 1, pp. 125–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Guerre-Millo, P. Gervois, E. Raspé et al., “Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity,” The Journal of Biological Chemistry, vol. 275, no. 22, pp. 16638–16642, 2000. View at Publisher · View at Google Scholar
  26. J. Rieusset, M. Roques, K. Bouzakri, E. Chevillotte, and H. Vidal, “Regulation of p85α phosphatidylinositol-3-kinase expression by peroxisome proliferator-activated receptors (PPARs) in human muscle cells,” FEBS Letters, vol. 502, no. 3, pp. 98–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. I. Pavo, G. Jermendy, T. T. Varkonyi et al., “Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 4, pp. 1637–1645, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, and I. Yamaguchi, “Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway,” Journal of the American College of Cardiology, vol. 43, no. 8, pp. 1481–1488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Ichihara, K. Obata, Y. Yamada et al., “Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors,” Journal of Molecular and Cellular Cardiology, vol. 41, no. 2, pp. 318–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Ogata, T. Miyauchi, S. Sakai, Y. Irukayama-Tomobe, K. Goto, and I. Yamaguchi, “Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts,” Clinical Science, vol. 103, supplement, pp. 284S–288S, 2002. View at Google Scholar · View at Scopus
  31. M. Rose, P. Balakumar, and M. Singh, “Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats,” Pharmacology, vol. 80, no. 2-3, pp. 177–184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Li, Q. Zhang, J. Zhang et al., “Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway,” BMC Cancer, vol. 14, article 96, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. G. S. Bhamra, D. J. Hausenloy, S. M. Davidson et al., “Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening,” Basic Research in Cardiology, vol. 103, no. 3, pp. 274–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. J. W. Calvert, S. Gundewar, S. Jha et al., “Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS- mediated signaling,” Diabetes, vol. 57, no. 3, pp. 696–705, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Paiva, N. P. Riksen, S. M. Davidson et al., “Metformin prevents myocardial reperfusion injury by activating the adenosine receptor,” Journal of Cardiovascular Pharmacology, vol. 53, no. 5, pp. 373–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. A. Bulhak, P.-O. Sjöquist, C.-B. Xu, L. Edvinsson, and J. Pernow, “Protection against myocardial ischaemia/reperfusion injury by PPAR-α activation is related to production of nitric oxide and endothelin-1,” Basic Research in Cardiology, vol. 101, no. 3, pp. 244–252, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. P. Jones, J. J. M. Greer, A. K. Kakkar et al., “Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 286, no. 1, pp. H276–H282, 2004. View at Google Scholar · View at Scopus
  38. A. Rubio-Guerra, “Is tetrahydrobiopterin a therapeutic option in diabetic hypertensive patients?” Integrated Blood Pressure Control, vol. 2010, no. 3, pp. 125–132, 2010. View at Publisher · View at Google Scholar
  39. N. J. Alp, M. A. McAteer, J. Khoo, R. P. Choudhury, and K. M. Channon, “Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atheroscleroses in ApoE-knockout mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 3, pp. 445–450, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Cai, N. J. Alp, D. McDonald et al., “GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation,” Cardiovascular Research, vol. 55, no. 4, pp. 838–849, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Wang, J. Xu, P. Song, B. Viollet, and M.-H. Zou, “In vivo activation of AMP-activated protein kinase attenuates diabetes-enhanced degradation of GTP cyclohydrolase I,” Diabetes, vol. 58, no. 8, pp. 1893–1901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. Z.-D. Ge, I. A. Ionova, N. Vladic et al., “Cardiac-specific overexpression of GTP cyclohydrolase 1 restores ischaemic preconditioning during hyperglycaemia,” Cardiovascular Research, vol. 91, no. 2, pp. 340–349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Liu, C. Lu, F. Li et al., “PPAR-agonist fenofibrate upregulates tetrahydrobiopterin level through increasing the expression of Guanosine 5′-triphosphate cyclohydrolase-I in human umbilical vein endothelial cells,” PPAR Research, vol. 2011, Article ID 523520, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Nieuwdorp, E. S. G. Stroes, and J. J. P. Kastelein, “Normalization of metabolic syndrome using fenofibrate, metformin or their combination,” Diabetes, Obesity and Metabolism, vol. 9, no. 6, pp. 869–878, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Krysiak, A. Gdula-Dymek, and B. Okopien, “Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance,” Pharmacological Reports, vol. 65, no. 2, pp. 429–434, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. R. Krysiak, A. Gdula-Dymek, and B. Okopień, “Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance,” Pharmacological Reports, vol. 65, no. 1, pp. 208–213, 2013. View at Publisher · View at Google Scholar · View at Scopus